Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide (TMAO) levels in patients with end-stage renal disease.

Study participants will undergo 3 study visits: baseline, day 7 (immediately post-therapy), day 21 (2 weeks post-therapy). All participants will provide blood and stool samples at each visit.

Inclusion Criteria:

• Diagnosis of end-stage renal disease
• Receiving chronic intermittent hemodialysis

Exclusion Criteria:

• Patients with less advanced kidney disease
• Inability or unwillingness to provide informed consent
• Patients who may be pregnant
• Hemodynamically unstable patients
• Patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease
• Patients with ongoing or recent infection and those with history of C-diff infection
• Patients with abnormal bowel structure secondary to surgical or anatomic variations
• Patients on certain medications, including immunosuppressants, antidiarrheal agents, or recent (within the last 2 months) use of antibiotics